Table 4.
Cost-effectiveness results among patients at first recurrence
| Outcomes | FMBL | SOC |
|---|---|---|
| Cost (2022 USD) | ||
| Total costs | $78,607 | $73,969 |
| Drug acquisition and administration costs | $23,956 | $16,908 |
| Medical costs | $54,652 | $57,061 |
| Effectiveness | ||
| Total QALYs | 10.394 | 10.056 |
| Total LYs | 12.549 | 12.235 |
| Incremental outcome of FMBL vs. SOC | ||
| Incremental costs | $4638 | |
| Incremental QALYs | 0.338 | |
| Incremental LYs | 0.314 | |
| ICER of FMBL vs. SOC (2022 USD) | ||
| Incremental cost per QALY gained | $13,727 | |
| Incremental cost per LY gained | $14,781 | |
ICER results are subject to rounding errors. Precise values of costs and effectiveness with more decimals were used in the model calculation
FMBL fecal microbiota, live-jslm, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year, SOC standard of care, USD United States dollar